Spirolactones: clinical and pharmacologic studies.
D000450:Aldosterone / Q000096:biosynthesis / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D002191:Canrenoic Acid / Q000494:pharmacology*; D002192:Canrenone / Q000494:pharmacology*; D004231:Diuresis / Q000187:drug effects; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D066298:In Vitro Techniques; D007668:Kidney / Q000378:metabolism; D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism; D013148:Spironolactone / Q000494:pharmacology*
D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes; D011956:Receptors, Cell Surface; D013148:Spironolactone; D000450:Aldosterone; D002192:Canrenone; D002191:Canrenoic Acid